文献速递炎症性肠病

胰高血糖素样肽-1受体激动剂用于2型糖尿病与炎症性肠病结局

Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-06-27

基于TriNetX数据库的回顾性队列研究,比较使用GLP-1受体激动剂与口服降糖药的溃疡性结肠炎或克罗恩病合并2型糖尿病患者的IBD结局。经倾向评分匹配后,GLP-1受体激动剂组静脉激素使用风险无差异,但结肠切除术(UC)和IBD相关手术(CD)风险较低。

要点

  • 溃疡性结肠炎GLP-1RA组结肠切除术风险低于对照组(aHR 0.37)。
  • 克罗恩病GLP-1RA组IBD相关手术风险低于对照组(aHR 0.55)。
  • 两组静脉激素使用及口服激素、进阶治疗启动风险均无差异。

核心结论

  • 在溃疡性结肠炎或克罗恩病合并2型糖尿病患者中,GLP-1受体激动剂的使用与较低的IBD相关手术风险相关。

研究设计与样本

  • 回顾性队列研究,利用TriNetX数据库比较溃疡性结肠炎或克罗恩病合并2型糖尿病患者使用GLP-1受体激动剂与口服降糖药的IBD特异性结局。
  • 溃疡性结肠炎GLP-1RA队列1130例(平均年龄58.9±11.6岁,女性56.3%,白人70.2%,肥胖57.2%),克罗恩病GLP-1RA队列1140例(平均年龄56.7±11.5岁,女性61.9%,白人73.6%,肥胖56.2%)。
  • 采用1:1倾向评分匹配,匹配人口学、合并症、BMI、实验室值、HbA1c及包括激素在内的IBD药物。

主要发现

  • 溃疡性结肠炎GLP-1RA组与对照组相比,静脉激素使用风险无差异(aHR 1.21,95%CI 0.92-1.59),结肠切除术风险较低(aHR 0.37,95%CI 0.14-0.97)。
  • 克罗恩病GLP-1RA组与对照组相比,静脉激素使用风险无差异(aHR 1.04,95%CI 0.80-1.34),手术风险较低(aHR 0.55,95%CI 0.36-0.84)。
  • 溃疡性结肠炎和克罗恩病GLP-1RA组与对照组相比,口服激素使用或进阶治疗启动风险均无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RA) show anti-inflammatory properties. AIM: To evaluate their clinical impact on inflammatory bowel disease (IBD) outcomes. METHODS: Retrospective cohort study utilising the TriNetX database comparing IBD-specific outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) and type 2 diabetes mellitus (T2DM) on GLP-1RA compared to oral hypoglycaemic agents. The primary outcome was hospitalisation requiring intravenous steroids and IBD-related surgery within 3 years. We performed 1:1 propensity score matching (PSM) for demographics, co-morbid conditions, BMI, laboratory values, HbA1c, and IBD medications including steroids. RESULTS: We identified 1130 patients in the UC GLP-1RA cohort (mean age: 58.9 ± 11.6 years, 56.3% female, 70.2% White, 57.2% with obesity) and 1140 patients in the CD GLP-1RA cohort (mean age: 56.7 ± 11.5, 61.9% female, 73.6% White, 56.2% with obesity). After PSM, there was no difference in the risk of intravenous steroid use (aHR: 1.21, 95% CI: 0.92-1.59) but a lower risk of colectomy (aHR: 0.37, 95% CI: 0.14-0.97) between the UC GLP-1RA and control cohort. There was no difference in the risk of intravenous steroid use (aHR: 1.04, 95% CI: 0.80-1.34) but a lower risk of surgery (aHR: 0.55, 95% CI: 0.36-0.84) between the CD GLP-1RA and CD control cohort. There was no difference in the risk of oral steroid use or advanced therapy initiation in the UC and CD GLP-1RA than control cohorts. CONCLUSIONS: We found an association between lower risk of IBD-related surgery and GLP-1RA use for T2DM in patients with UC or CD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Desai A, Petrov J, Hashash JG, et al. Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Aliment Pharmacol Ther. 2024. PMID: 38938071. doi:10.1111/apt.18138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。